CACNA1C polymorphisms Impact Cognitive Recovery in Patients with Bipolar Disorder in a Six-week Open-label Trial
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-07368-5
Abstract: Cognitive impairments in bipolar patients deteriorate as the disorder progresses. Little is known about whether genetic risks impact cognitive recovery during the course from depression to remission. In this six-week open-label trial, we shed light… read more here.
Keywords: recovery; impact cognitive; week open; cognitive recovery ... See more keywords
No long-term effects after a 3-week open-label placebo treatment for chronic low back pain: a 3-year follow-up of a randomized controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "Pain"
DOI: 10.1097/j.pain.0000000000002752
Abstract: Supplemental Digital Content is Available in the Text. A 3-year follow-up of 89 chronic back pain patients does not support the assumption that a 3-week open-label placebo treatment has long-term effects. read more here.
Keywords: label placebo; week open; placebo treatment; open label ... See more keywords
Asenapine add‐on treatment for schizophrenia adults who received antipsychotics: A 52‐week, open‐label study
Sign Up to like & getrecommendations! Published in 2023 at "Psychiatry and Clinical Neurosciences"
DOI: 10.1111/pcn.13540
Abstract: Asenapine is used to treat schizophrenia and bipolar I disorder. 1 Recent meta-analyses demonstrated that asenapine is well-tolerated and reduces overall symptoms in people with acute bipolar mania and schizophrenia. 2,3 Recently, a 52-week open-label,… read more here.
Keywords: week open; add treatment; treatment; open label ... See more keywords